Aerie Pharmaceuticals - AERI Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00%
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$15.25 As of 01/3/2023 01:00 AM ET

+0 (0.00%)

Get New Aerie Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AERI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AERI

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Aerie Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.25.

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Aerie Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/29/2022	Citigroup	Downgrade	Buy ➝ Neutral	$14.00 ➝ $15.25	Low
8/24/2022	Truist Financial	Downgrade	Buy ➝ Hold		Low
8/24/2022	HC Wainwright	Downgrade	Buy ➝ Neutral		Low
8/23/2022	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$15.00	Low
8/23/2022	Needham & Company LLC	Downgrade	Buy ➝ Hold		Low
8/23/2022	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$30.00 ➝ $15.25	Low
8/15/2022	Citigroup	Boost Target		$14.00	Low
8/9/2022	Citigroup	Boost Target		$14.00	N/A
2/28/2022	Citigroup	Lower Target		$23.00 ➝ $13.00	High
2/25/2022	Cowen	Lower Target		$30.00 ➝ $25.00	High
2/25/2022	Needham & Company LLC	Lower Target	Buy	$22.00 ➝ $14.00	High
12/17/2021	Needham & Company LLC	Initiated Coverage	Buy	$22.00	Medium
11/5/2021	Needham & Company LLC	Lower Target	Buy	$24.00 ➝ $22.00	High
9/17/2021	Needham & Company LLC	Initiated Coverage	Buy	$24.00	High
9/16/2021	HC Wainwright	Reiterated Rating	Buy	$29.00	High
9/10/2021	Needham & Company LLC	Initiated Coverage	Buy	$24.00	High
8/27/2021	Needham & Company LLC	Initiated Coverage	Buy	$24.00	Medium
8/20/2021	Needham & Company LLC	Initiated Coverage	Buy	$24.00	Medium
8/5/2021	Needham & Company LLC	Lower Target	Buy	$26.00 ➝ $24.00	Low
7/23/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
7/22/2021	Mizuho	Reiterated Rating	Buy	$28.00	High
7/16/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Medium
7/13/2021	Raymond James	Set Target		$15.65	Low
7/12/2021	Raymond James	Reiterated Rating	Hold		Low
7/9/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
7/2/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
4/30/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Medium
4/23/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Medium
3/1/2021	HC Wainwright	Reiterated Rating	Buy		High
2/5/2021	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
12/28/2020	Mizuho	Reiterated Rating	Buy	$28.00	N/A
12/28/2020	Needham & Company LLC	Reiterated Rating	Buy	$26.00	N/A
11/9/2020	HC Wainwright	Lower Target	Buy	$31.00 ➝ $29.00	High
11/6/2020	Mizuho	Reiterated Rating	Buy		High
10/19/2020	Bank of America	Downgrade	Neutral ➝ Underperform	$14.00 ➝ $9.00	High
10/5/2020	Raymond James	Reiterated Rating	Hold		High
10/5/2020	Needham & Company LLC	Reiterated Rating	Buy	$26.00	Medium
9/28/2020	Raymond James	Reiterated Rating	Hold		Medium
9/8/2020	Raymond James	Reiterated Rating	Hold		Medium
9/8/2020	Guggenheim	Initiated Coverage	Buy	$20.00	Medium
8/24/2020	Raymond James	Reiterated Rating	Hold		Medium
8/14/2020	Needham & Company LLC	Initiated Coverage	Buy	$26.00	Low
8/10/2020	Citigroup	Lower Target	Buy	$38.00 ➝ $32.00	Low
8/7/2020	Piper Sandler	Lower Target		$35.00 ➝ $25.00	Low
8/7/2020	Mizuho	Boost Target	Buy	$27.00 ➝ $29.00	High
8/7/2020	Needham & Company LLC	Lower Target	Buy	$32.00 ➝ $26.00	High
7/28/2020	Mizuho	Reiterated Rating	Buy	$29.00	Low
7/24/2020	Needham & Company LLC	Initiated Coverage	Buy	$32.00	Medium
7/6/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	High
6/26/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	Low
6/19/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	Medium
6/12/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	Low
6/5/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	High
5/29/2020	Oppenheimer	Initiated Coverage	Buy	$22.00 ➝ $24.00	High
5/29/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	High
5/22/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	N/A
5/7/2020	SunTrust Banks	Lower Target	Buy	$26.00 ➝ $22.00	Medium
5/7/2020	Needham & Company LLC	Reiterated Rating	Buy		High
5/7/2020	Mizuho	Lower Target	Buy	$34.00 ➝ $29.00	High
5/7/2020	Piper Sandler	Lower Target	Overweight	$45.00 ➝ $35.00	High
5/7/2020	HC Wainwright	Lower Target	Buy	$37.00 ➝ $31.00	High
4/30/2020	Needham & Company LLC	Lower Target	Buy	$40.00 ➝ $38.00	Low
4/24/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Medium
4/13/2020	Mizuho	Lower Target	Buy	$54.00 ➝ $34.00	Medium
4/13/2020	Oppenheimer	Lower Target	Outperform	$28.00 ➝ $26.00	Low
4/13/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
4/1/2020	Stifel Nicolaus	Lower Target	Buy	$45.00 ➝ $40.00	Medium
3/27/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	High
3/23/2020	Bank of America	Lower Target	Neutral	$26.00 ➝ $17.00	Low
3/23/2020	Bank of America	Reiterated Rating	Hold	$17.00	Low
2/28/2020	Mizuho	Reiterated Rating	Buy		Medium
2/21/2020	HC Wainwright	Lower Target	Buy	$41.00 ➝ $37.00	High
2/21/2020	JMP Securities	Reiterated Rating	Outperform ➝ Average	$35.00	High
2/16/2020	Needham & Company LLC	Reiterated Rating	Buy	$40.00	High
2/13/2020	Piper Sandler	Lower Target		$48.00 ➝ $45.00	Low
1/10/2020	Bank of America	Initiated Coverage	Neutral	$27.00	High
1/9/2020	SunTrust Banks	Initiated Coverage	Buy	$32.00	High
12/30/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	High
12/20/2019	Mizuho	Reiterated Rating	Buy	$54.00	High
12/19/2019	Citigroup	Initiated Coverage	Buy	$36.00	High
12/6/2019	Needham & Company LLC	Initiated Coverage	Buy	$40.00	Low
12/5/2019	Mizuho	Reiterated Rating	Buy	$54.00	High
11/29/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
11/18/2019	Needham & Company LLC	Reiterated Rating	Buy	$40.00	Low
11/7/2019	Oppenheimer	Lower Target		$45.00 ➝ $25.00	High
11/7/2019	JMP Securities	Lower Target	Outperform	$41.00	High
11/7/2019	Stifel Nicolaus	Lower Target	Buy	$77.00 ➝ $45.00	High
11/7/2019	Cowen	Reiterated Rating	Outperform	$105.00 ➝ $50.00	High
11/7/2019	HC Wainwright	Lower Target	Buy	$55.00 ➝ $41.00	High
11/7/2019	Cantor Fitzgerald	Lower Target	Overweight	$62.00 ➝ $30.00	High
11/7/2019	Mizuho	Reiterated Rating	Buy	$63.00 ➝ $54.00	High
10/25/2019	Needham & Company LLC	Reiterated Rating	Buy	$54.00	Low
10/24/2019	HC Wainwright	Reiterated Rating	Buy		High
10/18/2019	Mizuho	Set Target	Buy	$63.00	High
10/18/2019	Needham & Company LLC	Set Target	Buy	$54.00	High
10/15/2019	Piper Sandler Companies	Reiterated Rating	Buy		Low
10/11/2019	Mizuho	Set Target	Buy	$63.00	Low
10/11/2019	Needham & Company LLC	Set Target	Buy	$54.00	Low
10/4/2019	Needham & Company LLC	Reiterated Rating	Buy	$54.00	Low
9/27/2019	Needham & Company LLC	Set Target	Buy	$54.00	Low
9/27/2019	Mizuho	Set Target	Buy	$63.00	Low
9/13/2019	Mizuho	Set Target	Buy	$63.00	High
8/16/2019	Mizuho	Set Target	Buy	$63.00	High
8/8/2019	HC Wainwright	Reiterated Rating	Buy	$57.00	High
8/8/2019	Citigroup	Reiterated Rating	Outperform	$65.00 ➝ $45.00	High
8/8/2019	JMP Securities	Lower Target	Market Outperform	$58.00 ➝ $52.00	High
8/8/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$74.00 ➝ $54.00	High
8/8/2019	Piper Sandler Companies	Lower Target	Overweight	$76.00 ➝ $53.00	High
8/8/2019	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$85.00 ➝ $62.00	High
8/2/2019	Mizuho	Set Target	Buy	$77.00	Medium
7/24/2019	HC Wainwright	Reiterated Rating	Buy	$57.00	High
7/19/2019	Mizuho	Set Target	Buy	$77.00	N/A
7/10/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Positive	$74.00	Low
7/5/2019	Piper Sandler Companies	Set Target	Buy	$76.00	Low
7/2/2019	JMP Securities	Set Target	Average ➝ Outperform	$75.00 ➝ $58.00	High
5/8/2019	Piper Sandler Companies	Set Target	Buy	$76.00	High
4/21/2019	Mizuho	Reiterated Rating	Buy	$77.00	Medium

(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/22/2023

0 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

11/21/2023

0 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

0 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

0 very positive mentions
1 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

3/20/2024

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

No positive mentions tracked during this time.

Very Positive

No very positive mentions tracked during this time.

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Today's Range

Now: $15.25

$15.25

50 Day Range

MA: $15.23

$15.18

$15.25

52 Week Range

Now: $15.25

$4.81

$15.37

Volume

600 shs

Average Volume

974,748 shs

Market Capitalization

$753.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aerie Pharmaceuticals?: The following Wall Street analysts have issued research reports on Aerie Pharmaceuticals in the last twelve months: StockNews.com.
View the latest analyst ratings for AERI.
What is the current price target for Aerie Pharmaceuticals?: 0 Wall Street analysts have set twelve-month price targets for Aerie Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aerie Pharmaceuticals in the next year.
View the latest price targets for AERI.
What is the current consensus analyst rating for Aerie Pharmaceuticals?: Aerie Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AERI.
What other companies compete with Aerie Pharmaceuticals?: Other companies that are similar to Aerie Pharmaceuticals include Cullinan Oncology, Cabaletta Bio, CARGO Therapeutics, REGENXBIO and HilleVax. Learn More about companies similar to Aerie Pharmaceuticals.
How do I contact Aerie Pharmaceuticals' investor relations team?: Aerie Pharmaceuticals' physical mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company's listed phone number is (919) 237-5300 and its investor relations email address is [email protected]. The official website for Aerie Pharmaceuticals is www.aeriepharma.com. Learn More about contacing Aerie Pharmaceuticals investor relations.

Aerie Pharmaceuticals - AERI Stock Price Target and Predictions

Analyst Price Target for AERI

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Aerie Pharmaceuticals?

What is the current price target for Aerie Pharmaceuticals?

What is the current consensus analyst rating for Aerie Pharmaceuticals?

What other companies compete with Aerie Pharmaceuticals?

How do I contact Aerie Pharmaceuticals' investor relations team?